Physician profile
Ali A Khan
NPI 1588985782
$6,008.07
in general payments reported to CMS, 2019-2025
35 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $836 · 2023: $1,291 · 2024: $1,508 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,926.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $742.23 | 2021-2025 | Descovy, Yeztugo |
| Abbvie INC. | $675.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $622.86 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $567.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $505.65 | 2022-2025 | Dovato |
| Pfizer INC. | $403.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $360.44 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Madrigal Pharmaceuticals | $287.11 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $190.08 | 2022-2023 | Symtuza |
| Astellas Pharma US INC | $146.30 | 2023-2025 | Veozah, Cresemba |
| Lilly USA, LLC | $131.47 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $128.02 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $120.96 | 2021-2023 | Trintellix |
| Ferring Pharmaceuticals INC. | $104.36 | 2022-2024 | Rebyota |
| Sanofi-Aventis U.S. LLC | $98.96 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $85.51 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $80.25 | 2023-2025 | Repatha, Otezla, Otezla |
| Shionogi INC | $75.76 | 2023-2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.14 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $66.39 | 2023-2025 | Cologuard Collection Kit |
| Csl Behring | $54.45 | 2023 | Hizentra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.87 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $45.25 | 2023-2024 | Belbuca, Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.14 | 2021-2025 | Synjardy, Tradjenta, Jardiance |
| Indivior INC. | $42.24 | 2024 | Sublocade |
| Paratek Pharmaceuticals, INC. | $36.77 | 2022-2023 | Nuzyra |
| Abbott Laboratories | $35.47 | 2024 | Freestyle Libre 3 |
| W. L. Gore & Associates, INC. | $28.82 | 2025 | Gore Cardioform Septal Occluder |
| Shield Therapeutics INC | $28.37 | 2024-2025 | |
| Insulet Corporation | $24.96 | 2025 | Omnipod |
| Amarin Pharma, INC. | $18.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2022 | |
| Phadia US INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.